Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPα-low macrophages in non-Hodgkin lymphoma: Clinical results from a first-in-human Phase 1 study

Paolo Strati, Tatyana Feldman, Jelle Kylstra, Koby Kidder, Nathanael McCurley, Mehdi Al-Khalissi, Steven Ruck, Christiane Querfeld

Blood (2025) 146 (Supplement 1): 4148.

https://doi.org/10.1182/blood-2025-4148

Published: 2025

Journal Articles

BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients

Stefan Barta, Christiane Querfeld, Sean Lim, Ana Carneiro, Stephen Morris, Jeffrey Yachnin, Marica Vaapil, Susanne Gertsson, Petra Holmkvist, Ingrid Karlsson, Linda Mårtensson, Dmytro Piliuhin, Ingrid Teige, Johan Wallin, Björn Frendeus, Andres McAllister

Blood (2025) 146 (Supplement 1): 3633.

https://doi.org/10.1182/blood-2025-3633

Published: 2025

Journal Articles

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Blood (2025) 146 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2025-1875

Published: 2025

Journal Articles

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas

Christina Poh, Jasmine Zain, James Godfrey, Christiane Querfeld, Lu Chen, Sandrine Puverel, Pamela Allen, Alex Herrera

Blood (2025) 146 (Supplement 1): 1861.

https://doi.org/10.1182/blood-2025-1861

Published: 2025

Journal Articles

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Julia J. Scarisbrick, Pietro Quaglino, Sean Whittaker, Martine Bagot, Emmanuella Guenova, Evangelia Papadavid, Henry Miles Prince, Jose A. Sanches, Denis R. Miyashiro, Octavio Servitje, Christiane Querfeld, Oleg Akilov, Arvind Arumainathan, Luke Bennett, Maxime Battistella, Kim Benstead, Emilio Berti, Marie Beylot-Barry, Anne-Marie Busschots, Richard Cowan, Reinhard Dummer, Giles Dunnill, Teresa Estrach, Felicity Evison, Abraham Bashir, Larisa Geskin, Ale Gru, Joan Guitart, Melba C. Herrera, Emillia Hodak, Steve Horwitz, Constanze Jonak, Claus-Detlev Klemke, Robert Knobler, Pam Mckay, Marta Marschalkó, Cesare Massone, Rubeta Matin, Christina Mitteldorf, Robert Novoa, Pablo Ortiz-Romero, Nicola Pimpinelli, Ramon M. Pujol, Annmari Ranki, Liisa Vakeva, Kerri E. Rieger, Rudolf Stadler, Franz Trautinger, Johanna Latzka, Maarten Vermeer, Rachel Wachsmuth, Sophie Weatherhead, Ulrike Wehkamp, Marion Wobser, Youn H. Kim

Blood (2025) 146 (14): 1687–1692.

https://doi.org/10.1182/blood.2025029628

Published: 2025

Includes: Supplemental data

Journal Articles

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

Joo Y. Song, Weiwei Zhang, Michi M. Shinohara, Kord Honda, Christiane Querfeld, Julia Davidson, Krystie Chew, Lu Chen, Alexandra Hristov, Jasmine Zain, Anamarija M. Perry, Wing Chung Chan, Farah R Abdulla

Blood (2024) 144 (Supplement 1): 6225.

https://doi.org/10.1182/blood-2024-206611

Published: 2024

Journal Articles

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine Zain

Blood (2024) 144 (Supplement 1): 468.

https://doi.org/10.1182/blood-2024-205617

Published: 2024

Journal Articles

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Blood (2024) 144 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2024-200596

Published: 2024

Journal Articles

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Paolo Strati, Tatyana Feldman, Christiane Querfeld, Salvia Jain, Nathanael McCurley, Rita Bàrcia, Koby Kidder, Jelle Kylstra

Blood (2023) 142 (Supplement 1): 4856.

https://doi.org/10.1182/blood-2023-175040

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

Niloufer Khan, Esther Drill, Alison Moskowitz, Michi M Shinohara, Cecilia Larocca, Christiane Querfeld, Jasmine M. Zain, Steven M. Horwitz

Blood (2023) 142 (Supplement 1): 381.

https://doi.org/10.1182/blood-2023-173713

Published: 2023

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Jonathan Scott Rink, Stephen E. Henrich, Alexandra Moxley, Xu Hannah Zhang, Xiwei Wu, SonBinh Nguyen, Christiane Querfeld, David A. Horne, Steve T. Rosen, Leo I. Gordon, Colby Shad Thaxton, Adam Yuh Lin

Blood (2022) 140 (Supplement 1): 4934–4935.

https://doi.org/10.1182/blood-2022-158864

Published: 2022

Journal Articles

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Zhen Han, Xiwei Wu, Yate-Ching Yuan, Hanjun Qin, Chingyu Su, Jasmine Zain, Oleg E Akilov, Steve T Rosen, Mingye Feng, Christiane Querfeld

Blood (2022) 140 (Supplement 1): 6376–6377.

https://doi.org/10.1182/blood-2022-167670

Published: 2022

Journal Articles

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

H. Miles Miles Prince, Larisa J Geskin, Oleg E Akilov, Timothy M. Kuzel, Christiane Querfeld, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Francine M. Foss

Blood (2022) 140 (Supplement 1): 6577–6578.

https://doi.org/10.1182/blood-2022-167564

Published: 2022

Journal Articles

Mechanisms of resistance to mogamulizumab

Christiane Querfeld

Blood (2022) 139 (26): 3674–3676.

https://doi.org/10.1182/blood.2022016594

Published: 2022

Journal Articles

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Xu Cao, Yingyu Wang, Wencan Zhang, Xiancai Zhong, E. Gulsen Gunes, Jessica Dang, Jinhui Wang, Alan L. Epstein, Christiane Querfeld, Zuoming Sun, Steven T. Rosen, Mingye Feng

Blood (2022) 139 (22): 3290–3302.

https://doi.org/10.1182/blood.2021013901

Published: 2022

Includes: Supplemental data

Journal Articles

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Blood (2021) 138 (23): 2435–2440.

https://doi.org/10.1182/blood.2021012536

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Farah R Abdulla, Weiwei Zhang, Xiwei Wu, Kord Honda, Hanjun Qin, Hyejin Cho, Christiane Querfeld, Jasmine Zain, Steven T. Rosen, Wing C. Chan, Vishwas Parekh, Joo Y. Song

Blood (2021) 138 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2021-152051

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPα-low macrophages in non-Hodgkin lymphoma: Clinical results from a first-in-human Phase 1 study

BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

Genomic Studies in Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders Show Alterations That Differ from Aggressive CD30-Positive T-Cell Lymphomas

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Mogamulizumab in Patients with Mycosis Fungoides/Sézary Syndrome: Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing a 4-Weekly Dosing Schedule

Phase 1 Study of Autologous Sirpα-Low Macrophages (SIRPant-M) Administered By Intratumoral Injection Alone or in Combination with External-Beam Radiotherapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05967416)

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Quality of Life and Global Response Score in Cutaneous T-Cell Lymphoma

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Mechanisms of resistance to mogamulizumab

Targeting macrophages for enhancing CD47 blockade–elicited lymphoma clearance and overcoming tumor-induced immunosuppression

Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only